Current management of cervical cancer in Poland-Analysis of the questionnaire trial for the years 2002-2014 in relation to ASCO 2016 recommendations
- PMID: 30703105
- PMCID: PMC6354992
- DOI: 10.1371/journal.pone.0209901
Current management of cervical cancer in Poland-Analysis of the questionnaire trial for the years 2002-2014 in relation to ASCO 2016 recommendations
Abstract
Objectives: To assess the survival of patients with cervical cancer (CC). Since the recommendations concerning cervical cancer management adopted by Polish medical societies do not differ significantly from the ESGO or non-European guidelines, and the fact that evaluation of the system for CC treatment in Poland, as well as the mortality rate of Polish women with CC, which is 70% higher than the average for European Union (EU) countries, justifies the hypothesis that treatment of CC in Poland deviates from the Polish and international recommendations. This article puts forward the current management of cervical cancer in Poland and discusses it in the context of ASCO guidelines.
Material and methods: A survey retrospective multicenter analysis of the medical records of 1247 patients with cervical cancer who underwent treatment for disease and who had completed at least two years of follow-up.
Results: Although concurrent radiotherapy and chemotherapy is a standard treatment of FIGO IB to IVA cervical cancer patients in enhanced- and maximum-resources settings, in our analysis, we found that the percentage of women subjected to chemotherapy was lower than in countries where total survival rates were lower.
Conclusion: Within the IA to II A cervical cancer patients studied group, the methods of treatment remained in line with ASCO guidelines for countries with the highest standard of care. Although concurrent radiotherapy and chemotherapy is a standard treatment of FIGO IB to IVA cervical cancer patients in enhanced- and maximum-resources settings, in our analysis, we found that the percentage of women subjected to chemotherapy was lower than in countries where total survival rates were lower. Our findings, together with the inconsistencies within the cervical cancer screening program, may be one of the explanations of poorer survival rate of women with cervical cancer in Poland.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.Cent Eur J Public Health. 2016 Jun;24(2):163-8. doi: 10.21101/cejph.a4737. Epub 2016 May 13. Cent Eur J Public Health. 2016. PMID: 27178030
-
Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.Gynecol Oncol. 2021 Aug;162(2):277-283. doi: 10.1016/j.ygyno.2021.05.023. Epub 2021 May 29. Gynecol Oncol. 2021. PMID: 34059350
-
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.J Gynecol Oncol. 2017 Jan;28(1):e15. doi: 10.3802/jgo.2017.28.e15. J Gynecol Oncol. 2017. PMID: 27958682 Free PMC article.
-
Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.J Low Genit Tract Dis. 2019 Apr;23(2):87-101. doi: 10.1097/LGT.0000000000000468. J Low Genit Tract Dis. 2019. PMID: 30907775
-
[The guidelines for diagnostics and treatment of cervical cancer].Medicina (Kaunas). 2004;40(4):394-403. Medicina (Kaunas). 2004. PMID: 15111756 Review. Lithuanian.
Cited by
-
Cervical Cancer Prevention in the Era of the COVID-19 Pandemic.Medicina (Kaunas). 2022 May 29;58(6):732. doi: 10.3390/medicina58060732. Medicina (Kaunas). 2022. PMID: 35743995 Free PMC article.
-
Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients.Int J Womens Health. 2021 Feb 19;13:221-229. doi: 10.2147/IJWH.S289781. eCollection 2021. Int J Womens Health. 2021. PMID: 33642882 Free PMC article.
-
Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO).Cancers (Basel). 2024 Jul 15;16(14):2541. doi: 10.3390/cancers16142541. Cancers (Basel). 2024. PMID: 39061181 Free PMC article. Review.
References
-
- International Agency for Research on Cancer: GLOBOCAN 2012 Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
-
- Gelband H., Jha P., Sankaranarayanan R., Horton S. Cancer. Disease Control Priorities, third edition, vol. 3, International Bank for Reconstruction and Development / The World Bank, Washington, DC 20433, USA, 2015 - PubMed